Alchemab signs $415M licensing deal for ATLX-1282 with Eli Lilly
New agreement with Lilly to license ATLX-1282, a first-in-class IND-ready programme for neurodegenerative conditions targeting a novel receptor and mechanism Deal worth up to $415m including upfront...